Although the adverse effects on normal immune cells should be avoided, targeting STAT3 or Wnt/β-catenin pathway by specific inhibitor in tumor cells and immunosuppressive cells, or along with other immunotherapy, might restore the immunocompetence of EC patients. This evidence concerns the gene STAT3 and neoplasm.